The Imaging Response Assessment Team (IRAT) is a shared resource providing image-based tumor metrics for cancer research, as one of a national consortium of cancer center IRATs. The IRAT serves as a key component of investigator-initiated, cooperative group and industry-sponsored clinical trials at Moffitt, providing quantitative size-based measurements of tumor response. Year-to-year increases in the volume of service have generated the need for a cost center to support and institutionalize the Moffitt IRAT. The present proposal seeks to expand the capabilities and scope of this IRAT to support the infrastructure necessary for investigator-initiated studies at Moffitt.
The specific aims for the current effort are to support the IRAT infrastructure, which is used to: 1) Maintain the current quality of reported quantitative data and rapid response time;2) Expand the quantitative nature of reporting through more detailed image analysis;3) Coordinate acquisition and analysis of radiological images in support of clinical trials;4) Consult in clinical trials protocol submission;5) Review clinical trials in Scientific Review Committee;6) Provide pilot data for grant submissions;7) Assist in development of non-traditional imaging endpoints for response assessment, including participation in ACRIN and COG trials;and 8) Educate and reach out to Moffitt oncologists and investigators to increase awareness of new horizons in cancer imaging. These achievements are critical to accommodate the increasing complexity and importance of imaging biomarkers in response assessment, as the limitations and inadequacies of conventional metrics are recognized. An expansion of IRAT personnel is an immediate need to realize these goals. In 2009, 169 clinical trials with a primary imaging endpoint to assess tumor response were active, with the majority originating from the Experimental Therapeutics program, followed by Immunology. Of these, 71 were investigator-initiated, non-Industrial Moffitt or cooperative trials, and 94 had new patient accrual in 2009. These clinical trials spanned the breadth of Oncology Groups at Moffitt. The Core requests CCSG support of $153,973 which is 39% of its operational budget.

Public Health Relevance

The IRAT adds value to the CC mission by streamlining the process of integrating imaging into trials and providing QA/QC throughout the process, especially for trials not initiated by radiologists. Developing an infrastructure for the IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analysis, and novel biomarkers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-15
Application #
8495989
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$84,209
Indirect Cost
$34,233
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Song, Jinming; Hussaini, Mohammad; Zhang, Hailing et al. (2017) Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol 147:444-452
Tauro, Marilena; Shay, Gemma; Sansil, Samer S et al. (2017) Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Mol Cancer Ther 16:494-505
Davis, Stacy N; Christy, Shannon M; Chavarria, Enmanuel A et al. (2017) A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics. Cancer 123:1390-1400
Eksioglu, E A; Chen, X; Heider, K-H et al. (2017) Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia 31:2172-2180
Strom, Tobin; Harrison, Louis B; Giuliano, Anna R et al. (2017) Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer 84:304-314
Heit, Claire; Marshall, Stephanie; Singh, Surrendra et al. (2017) Catalase deletion promotes prediabetic phenotype in mice. Free Radic Biol Med 103:48-56
Chen, Yi; Fisher, Kate J; Lloyd, Mark et al. (2017) Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. Methods Mol Biol 1647:19-45
Kamath, Vidya P; Torres-Roca, Javier F; Eschrich, Steven A (2017) Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. Int J Genomics 2017:6576840
Liu, Ying; Balagurunathan, Yoganand; Atwater, Thomas et al. (2017) Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res 23:1442-1449
Stewart, Paul A; Fang, Bin; Slebos, Robbert J C et al. (2017) Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. Proteomics 17:

Showing the most recent 10 out of 1137 publications